Blood tests for Alzheimer’s disease are rapidly moving into clinics, promising earlier and easier detection of brain changes linked to dementia. Yet new research suggests that when those tests come back with high levels of Alzheimer’s biomarkers, the signal may be coming from the kidneys as much as from the brain. That possibility is forcing neurologists and nephrologists to rethink what “positive” really means when the body’s main filtration system is not working well.
Instead of treating every elevated result as a red flag for impending memory loss, clinicians are being urged to look more closely at kidney function first. The emerging evidence points to a more complicated story in which impaired kidneys allow Alzheimer’s-related proteins to build up in the bloodstream, potentially mimicking or exaggerating brain disease even when dementia risk itself is not clearly higher.
Why kidney health is suddenly central to Alzheimer’s blood tests
The promise of Alzheimer’s blood tests rests on the idea that certain proteins, including amyloid fragments, phosphorylated tau and neurofilament light chain, leak from a damaged brain into the circulation. I see the new data on kidney function as a reminder that the bloodstream is not a direct pipeline from brain to lab, it is a shared space where other organs, especially the kidneys, constantly shape what shows up in a vial. When those filters falter, the concentration of brain-derived proteins can rise even if the brain itself has not changed.
Researchers tracking dementia risk have now reported that people with impaired kidney function tend to have higher levels of proteins in their blood that are linked to Alzheimer’s disease, even when their cognitive status looks similar to people with healthier kidneys. In one analysis, people with reduced filtration had elevated Alzheimer’s biomarkers in the blood, a pattern that suggests the kidneys are influencing how much of these proteins linger in circulation rather than simply reflecting more aggressive brain pathology, a finding highlighted in new reporting on Alzheimer’s biomarkers in the blood.
What the latest study actually found about dementia risk
One of the most striking aspects of the new research is what it did not show. Investigators looking at large groups of older adults with varying levels of kidney function did not find that reduced kidney performance itself clearly increased the risk of developing dementia over the study period. That runs counter to the intuitive fear that if Alzheimer’s biomarkers are higher in the blood, dementia must be more likely, and it underscores how easily blood-based signals can be misread when the role of other organs is ignored.
In fact, the study’s authors emphasized that, “While we did not find that having reduced kidney function increased the risk of developing dementia, we did find that people with impaired kidney function had higher levels of proteins in their blood that are linked to Alzheimer’s disease,” a distinction that has been echoed in coverage of how While we did not find dementia risk rising, the biomarker levels clearly did. That nuance matters for patients who might otherwise interpret a “high” result as a near-certain forecast of cognitive decline when, in reality, their kidneys may be the main driver of the lab number.
How impaired kidneys distort Alzheimer’s biomarker levels
To understand why kidney disease can skew Alzheimer’s blood tests, it helps to look at how precisely researchers have mapped the relationship between filtration and biomarker levels. Kidney function is often measured by estimated glomerular filtration rate, or eGFR, which reflects how much blood the kidneys can clear of waste each minute. In the new work, scientists modeled biomarker concentrations across a range of eGFR values and found that as filtration dropped, the levels of several Alzheimer’s-related proteins climbed in a nonlinear pattern.
At an eGFR of 30 mL/min/1.73 m2, the estimated differences in biomarker levels were β = 0.22, 0.20, 0.24, 0.88, and 0.10 for key Alzheimer’s proteins, a set of figures that illustrates how strongly impaired filtration can inflate blood readings even before dementia appears, as detailed in an analysis of how 1.73 m relates to rising biomarker values. When I look at those numbers, I see a clear warning: without adjusting for kidney function, clinicians risk overcalling Alzheimer’s pathology in people whose main problem is that their kidneys are no longer clearing proteins efficiently.
Brain health, kidney health, and the shared biology behind them
The emerging picture is not simply that kidneys confuse Alzheimer’s tests, it is that brain and kidney health are intertwined in ways that researchers are only beginning to untangle. Both organs rely on dense networks of small blood vessels that are vulnerable to the same insults, including high blood pressure, diabetes and chronic inflammation. When those vessels stiffen or clog, the kidneys can lose filtration capacity and the brain can lose the steady blood flow it needs, creating parallel tracks of risk that show up as subtle cognitive changes on one side and rising creatinine on the other.
Reporting on the new data has framed this as a story in which Brain health might be linked to kidney health, with Key Takeaways noting that People with impaired kidneys had higher levels of Alzheimer’s-related proteins in their blood, even when dementia itself did not surge in lockstep. That framing reflects a growing consensus that the same vascular and metabolic forces that damage the kidneys can also accelerate neurodegeneration, a connection highlighted in coverage of how Brain health might be linked to kidney function.
Why high biomarkers may be a kidney problem, not a brain crisis
For patients and families, the most unsettling part of any Alzheimer’s test is the fear that a positive result locks in a grim future. The new kidney-focused findings complicate that narrative in a way that is both challenging and, in some respects, reassuring. If impaired kidneys are responsible for a substantial share of elevated biomarkers, then a high reading does not automatically mean the brain is deteriorating faster, it may instead be a sign that the body’s filtration system is failing to clear proteins that would otherwise be removed.
Researchers studying Chronic Kidney Disease Human Organs Kidney function have argued that poor kidney health may not raise dementia risk on its own, but it can shift how fast dementia symptoms appear and how reliable blood-based tests are at any given moment. In their view, the kidneys act as a kind of volume knob on Alzheimer’s biomarkers in the bloodstream, amplifying or muting the signal regardless of what is happening inside the skull, a perspective captured in new work on how Chronic Kidney Disease Human Organs Kidney dynamics shape biomarker readings.
Association, not proof: what the science can and cannot say
It is tempting to leap from association to causation, especially when the stakes involve dementia, but the researchers behind the latest work have been careful to draw a line. They have stressed that their data show a strong link between poor kidney function and elevated Alzheimer’s markers in the blood, not definitive proof that kidney disease causes those markers to rise or that treating the kidneys will automatically normalize the tests. That distinction is crucial for patients who might otherwise chase unproven therapies or assume that improving kidney numbers will erase every trace of Alzheimer’s risk.
One summary of the findings put it plainly, noting that the study does not prove that poor kidney function causes higher levels of Alzheimer’s biomarkers in the blood, it only shows an association between reduced filtration and elevated proteins. I read that as a call for humility in how clinicians interpret and communicate these results, a reminder that correlation can guide further research but cannot, on its own, settle questions of cause and effect, a point underscored in reporting that the study does not prove a direct causal pathway.
How clinicians may need to adjust Alzheimer’s testing in kidney disease
For front-line clinicians, the practical question is how to fold kidney function into the growing use of Alzheimer’s blood tests. I expect that, over time, neurologists and primary care doctors will treat eGFR the way cardiologists treat cholesterol when interpreting a stress test, as a contextual factor that can shift the meaning of a borderline or high result. In patients with known chronic kidney disease, a single elevated biomarker may prompt a closer look at filtration rates and other lab values before anyone delivers a definitive Alzheimer’s label.
Some experts have already suggested that neurofilament light chain, or NfL, may be particularly sensitive to kidney function, with reports that kidneys help human health by clearing this protein and that there is a notable association between reduced kidney performance and high NfL levels. That pattern implies that clinicians might need different reference ranges or interpretive cutoffs for patients with impaired kidneys, especially when using NfL to track neurodegeneration over time, a concern reflected in coverage of how kidneys help human health by clearing these proteins.
The public’s blind spot on kidney function
All of this hinges on a basic piece of health literacy that, for many people, is missing: understanding what the kidneys do and how to know when they are in trouble. Surveys of patients and the general public have repeatedly found that kidney disease is both common and poorly understood, with many individuals unable to explain what eGFR means or why high blood pressure and diabetes are such potent threats to renal function. That knowledge gap makes it harder for people to grasp why their kidney numbers should matter when they are sitting in a neurologist’s office discussing memory lapses.
One kidney knowledge survey led by Dr. Lazowski concluded that there is a pressing need to educate the public not only about kidney disease and its risk factors, but about basic kidney function itself, and it pointed readers toward resources such as the National Kidney Foundation for more information. I see that as a direct challenge to health systems and advocacy groups to integrate kidney education into broader conversations about aging and brain health, a need that was highlighted in the finding that This study shows the need for much stronger public understanding of renal function.
Protecting kidneys as part of a brain health strategy
If kidney function can distort Alzheimer’s blood tests and potentially influence how quickly dementia symptoms emerge, then protecting the kidneys becomes part of a broader brain health strategy. That does not mean there is a simple formula in which a certain eGFR guarantees cognitive resilience, but it does mean that the same habits that preserve filtration capacity, from blood pressure control to avoiding unnecessary nephrotoxic drugs, may also help keep biomarker readings more interpretable and the brain’s microvasculature in better shape. In practical terms, that is a call to bring nephrology and neurology closer together in preventive care.
Guides for patients now emphasize a handful of concrete steps to protect kidney health, including managing diabetes, keeping blood pressure in check, staying hydrated, avoiding excessive use of nonsteroidal anti-inflammatory drugs like ibuprofen, and getting regular kidney function tests when risk factors are present. Those recommendations are not framed around dementia, but in light of the new biomarker data, they double as a way to reduce one major source of noise in Alzheimer’s blood testing, a connection that becomes clearer when looking at a 6-step guide to protecting kidney health.
What patients should ask when Alzheimer’s blood tests and kidney issues collide
For patients who already live with chronic kidney disease, the new findings raise immediate questions about how to interpret any Alzheimer’s blood test their doctor might order. I would encourage those patients to ask, before the blood is drawn, whether their eGFR and other kidney markers will be factored into the interpretation, and whether alternative assessments, such as cognitive testing or imaging, might be more informative in their specific case. The goal is not to avoid biomarker testing altogether, but to ensure that its limitations are acknowledged upfront.
People with impaired kidneys who receive a report showing elevated Alzheimer’s biomarkers should also feel empowered to ask whether the result could be partly or largely driven by reduced filtration, and whether repeat testing after stabilizing kidney function might yield a clearer picture. Reporting on the latest research has already framed the issue in terms of Key Takeaways that stress how People with impaired kidneys had higher levels of Alzheimer’s-linked proteins without a matching surge in dementia diagnoses, a nuance that patients can bring into the exam room by asking their clinicians to explain how those Key Takeaways apply to their own situation.
More from MorningOverview